Amgen Inc. (NASDAQ:AMGN) posted its earnings results on Tuesday. The medical research company reported $3.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16, Bloomberg Earnings reports. The company had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a net margin of 34.42% and a return on equity of 29.37%. Amgen’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period last year, the company posted $2.84 earnings per share.

Shares of Amgen (NASDAQ AMGN) traded down 0.09% on Tuesday, hitting $180.89. 3,343,223 shares of the stock were exchanged. The stock has a market cap of $133.03 billion, a PE ratio of 17.18 and a beta of 1.35. The company’s 50 day moving average is $170.78 and its 200-day moving average is $165.90. Amgen has a 52-week low of $133.64 and a 52-week high of $184.21.

In related news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction that occurred on Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total transaction of $451,156.80. Following the sale, the senior vice president now directly owns 24,214 shares in the company, valued at $3,738,641.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.20% of the stock is currently owned by corporate insiders.

AMGN has been the subject of several research analyst reports. ValuEngine cut shares of Amgen from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $189.00 price objective on shares of Amgen in a research report on Thursday, April 6th. BidaskClub upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. Robert W. Baird reiterated a “neutral” rating and set a $165.00 price objective on shares of Amgen in a research report on Friday, April 28th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $195.00 price objective on shares of Amgen in a research report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, twelve have issued a buy rating and three have assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $185.21.

ILLEGAL ACTIVITY WARNING: “Amgen Inc. (AMGN) Announces Quarterly Earnings Results, Beats Estimates By $0.16 EPS” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/25/amgen-inc-amgn-announces-quarterly-earnings-results-beats-estimates-by-0-16-eps.html.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Earnings History for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.